GPC3 and hepatocellular carcinoma: The F(ab’)2 fragment is further engineered for T cell therapy targeting GPC3-positve HCCs in a Phase 1/2 clinical trial (NCT04864054); our goal is to use the same GPC3 antibody to develop a complementary diagnostic tool to aid in the identification of GPC3-positive HCC patients who would be suitable candidates for such therapy.